Summary. Using two‐colour phenotypic analysis with anti‐CD38 antibody, human myeloma cells can be classified into VLA‐5− immature and VLA‐5+ mature cells. We examined the relationship between variations of these subpopulations and clinical responses during treatment in multiple myeloma (MM). 39 patients with MM were treated with combined chemotherapy. First estimation of clinical responses after induction therapy showed that early clinical responses were correlated with the percentage of immature myeloma cells present after induction therapy (P < 0.01), not at diagnosis. After three courses of cyclic maintenance therapy, immature myeloma cells significantly decreased in proportion along with a decrease in total myeloma cells in maintained or more responsive cases (P < 0.01). On the other hand, immature myeloma cells were still found in high proportions in non‐responsive cases with no change (NC) or minor response (MR) (P < 0.01). Furthermore, in relapsing cases from partial response (PR) or progressive disease (PD) from non‐responsive cases, immature myeloma cells increased markedly. Therefore these results show that high proportions of VLA‐5− immature myeloma cells remaining after induction therapy and during maintenance therapy correlate well with a declining clinical course of MM during maintenance therapy.
|Number of pages||5|
|Journal||British Journal of Haematology|
|Publication status||Published - 12-1995|
All Science Journal Classification (ASJC) codes